Ποια είναι η τιμή για MetaVia Inc. (MTVA)

Η τιμή για MetaVia Inc. (MTVA) είναι $1.51

Ποια είναι η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA)

Η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA) είναι $3.32M

MetaVia Inc. (MTVA) Τιμή και Κεφαλαιοποίηση Αγοράς

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Η τιμή για MTVA	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$2,476,400 $3.32M	NVDA	$5.452T	+163,999,879.82%
$2,039,500 $3.32M	AAPL	$4.490T	+135,066,129.25%
$1,890,688 $3.32M	GOOG	$4.162T	+125,211,057.07%
$1,669,904 $3.32M	MSFT	$3.676T	+110,589,539.25%
$1,286,852 $3.32M	AMZN	$2.833T	+85,221,874.59%

Η τιμή για MTVA

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$2,476,400 $3.32M